Calgary, Alberta–(Newsfile Corp. – July 25, 2022) – NurExone Biologic Inc. (TSXV: NRX) (“NurExone” or the “Company”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System (“CNS”) indications, is pleased to announce that it will showcase a poster presentation at the prestigious “Understanding Extracellular Vesicle Biogenesis and Composition for Detection and Treatment of Diseases” conference, hosted by Gordon Research Conference’s (“GRC”) in Newry, Maine, U.S. read more